
Apaluside 60mg Tablet
Salt Composition: Apalutamide
Expiry Date: 01/2028
Inclusive of all taxes
120 tablet(s) in a bottle
About The Product
PROSTATE CANCER
Description
Apaluside 60mg tablet is a prescription based medication which is highly used medication in advanced prostate cancer in adult men. The medication is a selective androgen receptor (AR) inhibitor, that binds directly to the androgen (testosterone).
It inhibits the formation of protein which is responsible for the production of cancer cells and reduces cancer cell growth or increases cell death. Apalutamide is an active ingredient of Apaluside responsible for these anti-cancer effects.
Doctor supervision is needed in the treatment to ensure correct dosage and monitor for side effects.
Indication
Treat advanced prostate cancer in adult men.
Common Side Effects
● Brain tumor
● Diabetes
● Head injury
● Heart disease
● High blood pressure
● High cholesterol
● Osteoporosis, weak bones
● Seizures
● Stroke
Dosage And Duration
- Apaluside tablet should be taken orally in 60mg concentration.
- Take the medicine with or without food at the same time everyday.
- Dose adjustment may be required in patients with severe liver impairment or those experiencing significant adverse effects.
- Patient should be monitored for signs of prostate cancer progression, liver function and overall health status.
Mechanism Of Action
Apalutamide works by binding to the androgen receptor in prostate cancer cells and blocking the production of testosterone which is responsible for growing cancer cells in the body. This action inhibits the signaling pathways that drives the growth and proliferation of prostate cancer cells.
This helps slow the progression of the disease, induces apoptosis of malignant cells, thereby contributing to improved clinical outcomes in patients with advanced prostate cancer.
Safety Advice
Faqs
Apaluside 60mg treats advanced prostate cancer in adult men by blocking the progression of androgen hormones which is responsible for the production of cancer cells in the body.
References
• Chi, K. N., Agarwal, N., Bjartell, A., Chung, B.
H., Pereira de Santana Gomes, A. J., Given, R., ... & Chowdhury, S.
(2019). Apalutamide for metastatic, castration-sensitive prostate cancer.
New England Journal of Medicine, 381(1), 13-24. • Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B.
A., Graff, J. N., ... & Small, E.
J. (2021).
Apalutamide and overall survival in prostate cancer. European urology, 79(1), 150-158. • Smith, M.
R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J.
N., ... & Small, E. J.
(2018). Apalutamide treatment and metastasis-free survival in prostate cancer.
New England Journal of Medicine, 378(15), 1408-1418. • Rathkopf, D. E., & Scher, H.
I. (2018).
Apalutamide for the treatment of prostate cancer. Expert review of anticancer therapy, 18(9), 823-836. • Al-Salama, Z.
T. (2018).
Apalutamide: first global approval. Drugs, 78(6), 699-705.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
